Incretin based therapy and pancreatic cancer: Realising the reality

doi:10.3748/wjg.v28.i25.2881

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 25

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5664)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

343

WORD

HTML

2903

Figures (1-1)

319

Tables (1-3)

284

Sum=3916

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

195

Download

429

Sum=624

Publishing Process of This Article

Item

Count

Browse

321

Download

803

Sum=1124

Jul 7, 2022 (publication date) through May 20, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jul 7, 2022; 28(25): 2881-2889
Published online Jul 7, 2022. doi: 10.3748/wjg.v28.i25.2881

Table 1 Various incretin-based therapies

Class of drugs	Medications
GLP-1RA (oral/subcutaneous)	Subcutaneous-Exenatide, Albiglutide, Lixisenatide, Liraglutide, Semaglutide. Oral-Semaglutide
DPP-4I (oral)	Saxagliptin, Vildaglipitn, Sitagliptin, Aloglipitn, Linagliptin, Teneligliptin
Newer drugs/drugs in development	Tirzepatide (GLP1 + GIP co-agnoist)
	Cotadutide (GLP1 + glucagon co-agonist)
	Teduglutide (GLP-2 RA)
	Triple agnoists (GLP1 + Glucagon + GIP agnoists)

GLP-1RA: Glucagon like peptide receptor-1 receptor agonist; DPP-4I: Dipeptidyl peptidase-4 inhibitor; GIP: Gastric inhibitory peptide; GLP-2RA: Glucagon like peptide receptor-2 receptor agonist.

Citation: Suryadevara V, Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R. Incretin based therapy and pancreatic cancer: Realising the reality. World J Gastroenterol 2022; 28(25): 2881-2889
URL: https://www.wjgnet.com/1007-9327/full/v28/i25/2881.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i25.2881